REVENUE MEMORANDUM CIRCULAR NO. 100-2024 issued on September 5, 2024 publishes the full text of the August 7, 2024 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate endorsing updates to the List of VAT-Exempt Products under Republic Act (RA) No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act), which now includes certain medicines for cancer, diabetes, hypertension, kidney diseases, mental illness and tuberculosis.

As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.